cpp-115
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01493596)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Gamma-amino-N-butyrate transaminaseINHIBITOR
ABAT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
N[C@H]1C[C@@H](C(=O)O)CC1=C(F)F- Mol. weight
- 177.15 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297273 ↗
- ChEMBLCHEMBL146927 ↗
Also known as
- (1s,3s)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid
- 3-a-4-dfmcpca cpd
- 3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
- cpp-115
- cpp-115
- cpp-115
- cpp-115 free base
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01493596 | Phase 1 | Dec 1, 2011 | Catalyst Pharmaceuticals, Inc., Clinilabs |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Catalyst Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2011 |
| Clinilabs | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1